Tausche AK, et al. - A 6-month phase 3 clinical trial and extension study are performed to research the effectiveness and safety of lesinurad, a selective uric acid reabsorption inhibitor. In patients with gout and intolerance/contraindication to XOIs, lesinurad 400 mg monotherapy showed superior sUA lowering compared with placebo, with sustained impacts for up to 18 months. Because of a high incidence of serum creatinine elevations and renal-related adverse events, including serious adverse events with lesinurad 400 mg, lesinurad ought not to be utilized as monotherapy.